Royalty Pharma plc (RPRX) — Net Income
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | $770.95M | -10.2% |
| 2024 | $858.98M | -24.3% |
| 2023 | $1.13B | +2549.5% |
| 2022 | $42.83M | -93.1% |
| 2021 | $619.73M | -36.4% |
| 2020 | $975.04M | -58.5% |
| 2019 | $2.35B | +70.5% |
| 2018 | $1.38B | — |
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | $770.95M | -10.2% |
| 2024 | $858.98M | -24.3% |
| 2023 | $1.13B | +2549.5% |
| 2022 | $42.83M | -93.1% |
| 2021 | $619.73M | -36.4% |
| 2020 | $975.04M | -58.5% |
| 2019 | $2.35B | +70.5% |
| 2018 | $1.38B | — |